Grant Yonehiro

Maxygen, Inc. is a biotechnology company. It is focused on the potential further development of its MAXY-G34 product, a next-generation pegylated, granulocyte colony stimulating factor, G-CSF, for the treatment of chemotherapy induced neutropenia and acute radiation syndrome. G-CSF is a natural protein that functions by stimulating the body's bone marrow to produce more white blood cells. The company was founded on May 7, 1996 and is headquartered in San Mateo, CA.

GenVec, Inc. operated as a clinical-stage gene delivery company, which engaged in the development of therapeutics and vaccines. The firm designs, tests, and manufactured adenoviral-based product candidates using its proprietary AdenoVerse platform. Its products included CGF166-Hearing Loss; GV2311-RSV Vaccine; and GV2207-HSV-2 Immunotherapeutic. The company was founded in December 1992 and was headquartered in Rockville, MD.

Perseid Therapeutics LLC was founded in September 2009 to discover and develop novel protein pharmaceuticals utilizing Molecular BreedingTM (also commonly referred to as DNA shuffling). It seeks to develop products that deliver significant patient benefit both by improving upon known protein therapies and also by discovering new therapeutic modalities. Perseid has initially focused its efforts treating disorders through therapeutics that modulate the immune system. Perseid Therapeutics is a joint venture between Maxygen, Inc. and Astellas Pharma Inc. with Maxygen owning approximately 83%, and Astellas Pharma owning the remaining approximately 17%. As part of the joint venture arrangement, Astellas has been granted an option until September of 2012 to acquire all of Perseid ownership at pre-specified prices that increase on a quarterly basis. The launch of Perseid completed Maxygen’s multi-year strategic process whereby most of Maxygen’s assets are in arrangements under which external parties are primarily responsible for funding.

Berkeley Lights, Inc. engages in rapid development and commercialization of biotherapeutics and other cell-based products. Its platform captures deep phenotypic, functional and genotypic information for tens of thousands of single cells in parallel and can also deliver the live biology customers desire in the form of the best cells. It operates through the following geographical segments: North America, Asia Pacific, and Europe. The company was founded by Igor Y. Khandros, William H. Davidow, Michael E. Marks, and Ming C. Wu on April 5, 2011 and is headquartered in Emeryville, CA.

Vium, Inc. provides technology for preclinical drug discovery services. It offers biomedical investigators with technology that accelerates the preclinical drug discovery and development pipeline. The company was founded by Timothy L. Robertson and Jonathan Betts-Lacroix in 2013 and is headquartered in San Mateo, CA.